Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma-Reference-Cited by-同舟云学术

Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma

Published:2021-10-19 Issue:10 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Gallagher Andrew¹,Edwards Michaela²,Nair Parameswaran³,Drew Stewart⁴,Vyas Aashish⁵,Sharma Rashmi⁶,Marsden Paul A⁵⁷⁸,Wang Ran⁹¹⁰,Evans David JW¹¹

Affiliation:

1. Lancaster Medical Practice; Lancaster UK

2. Nottingham Business School; Nottingham Trent University; Nottingham UK

3. Firestone Institute for Respiratory Health; McMaster University & St Joseph`s Healthcare; Hamilton Canada

4. Children’s Physiotherapy Service; Lancashire Care NHS Foundation Trust; Preston UK

5. Department of Respiratory Medicine; Lancashire Teaching Hospitals Trust; Preston UK

6. Department of Microbiology; BTH NHS Foundation Trust; Blackpool UK

7. North West Lung Centre; Wythenshawe Hospital, Manchester University NHS Foundation Trust; Manchester UK

8. Division of Infection, Immunity and Respiratory Medicine; School of Biological Sciences, University of Manchester; Manchester UK

9. Department of Respiratory Medicine; Manchester University NHS Foundation Trust; Manchester UK

10. Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences; University of Manchester; Manchester UK

11. Lancaster Medical School; Lancaster University; Lancaster UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference235 articles.

1. Borish LC Nelson HS Bensch G Corren J Busse W Whitmore J Phase I/II study of soluble interleukin-4 receptor (il-4r) in adults with moderate asthma European Respiratory Society 9th Annual Congress; 1999 Oct 9-13; Madrid 1999 P1983

2. Phase I/II study of recombinant interleukin-4 receptor (IL-4R) in adult patients with moderate asthma;Borish;American Journal of Respiratory and Critical Care Medicine,2000

3. Phase I/II study of interleukin-4 receptor (IL-4R) in moderate asthma;Borish;American Journal of Respiratory and Critical Care Medicine,1998

4. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial;Borish;American Journal of Respiratory and Critical Care Medicine,1999

5. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma;Borish;Journal of Allergy and Clinical Immunology,2001

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Network pharmacology prediction, molecular docking, and molecular dynamics simulation-based strategy to explore the potential mechanism of Huashanshen dripping pill against asthma;Journal of Pharmacy and Pharmacology;2024-07-17

2. Immunotherapeutic implications on targeting the cytokines produced in rhinovirus-induced immunoreactions;Frontiers in Allergy;2024-05-27

3. IL-4 activates ULK1/Atg9a/Rab9 in asthma, NLRP3 inflammasomes, and Golgi fragmentation by increasing autophagy flux and mitochondrial oxidative stress;Redox Biology;2024-05

4. Type 2 airway inflammation in COPD;European Respiratory Journal;2024-03-14

5. Immunomodulation of Myocardial Fibrosis;JACC: Basic to Translational Science;2023-11